Aptorum Group (APM) Stock Price, News & Analysis

Company Overview

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.

Key Stats

• Today's Range: $0.90 to $0.97
• 50-Day Range: $0.71 to $1.08
• 52-Week Range: $0.46 to $7.49
• Volume: 11,115 shs
• Average Volume: 613,344 shs
• Market Capitalization: $4.82 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Aptorum Group Stock Analysis - MarketRank™

Aptorum Group scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Aptorum Group.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Aptorum Group has a P/B Ratio of 0.30. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.10% of the float of Aptorum Group has been sold short.

Short Interest Ratio / Days to Cover

Aptorum Group has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aptorum Group has recently increased by 82.82%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aptorum Group does not currently pay a dividend.

Dividend Growth

Aptorum Group does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.10% of the float of Aptorum Group has been sold short.

Short Interest Ratio / Days to Cover

Aptorum Group has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aptorum Group has recently increased by 82.82%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for APM on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Aptorum Group insiders have not sold or bought any company stock.

Percentage Held by Insiders

63.99% of the stock of Aptorum Group is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 3.80% of the stock of Aptorum Group is held by institutions.

APM Stock Analysis - Frequently Asked Questions

How have APM shares performed this year?

Aptorum Group's stock was trading at $2.80 at the beginning of the year. Since then, APM shares have decreased by 67.8% and is now trading at $0.9015.
View the best growth stocks for 2025 here.

When did Aptorum Group's stock split?

Aptorum Group's stock reverse split on the morning of Monday, January 23rd 2023. The 1-10 reverse split was announced on Monday, January 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Aptorum Group?

Shares of APM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Aptorum Group own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aptorum Group investors own include Pfizer (PFE), Meta Platforms (META), Adobe (ADBE), Cisco Systems (CSCO), Walt Disney (DIS), Gilead Sciences (GILD) and Amgen (AMGN).

Company Calendar

• Today: 5/21/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:APM
• CIK: 1734005
• Web: www.aptorumgroup.com
• Phone: 442080929299
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.24
• Current Ratio: 1.16
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $430,000.00
• Price / Sales: 11.21
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.97 per share
• Price / Book: 0.30

Miscellaneous

• Outstanding Shares: 5,347,000
• Free Float: 1,866,000
• Market Cap: $4.82 million
• Optionable: Not Optionable
• Beta: -0.16